No, Johnson & Johnson should not be allowed to charge leukemia patients $160,000 per year for IMBRUVICA while raking in a gross yearly profit of $65 billion. Any surprise that J&J is now trying to sue the government for letting Medicare negotiate lower drug prices. We need to stop Big Pharma's price gouging.